Cargando…
‘Use of lipid-lowering therapy: the guidelines, the drugs or the patient?’
The current step up approach in the therapy of dyslipidemias aims to reduce the amount of LDL cholesterol below a threshold that varies according to the patient's risk category, with a pharmacological approach that sees statins as a fundamental cornerstone. Although absolutely functional in red...
Autores principales: | Borghi, Claudio, Bragagni, Alessio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653137/ https://www.ncbi.nlm.nih.gov/pubmed/36380777 http://dx.doi.org/10.1093/eurheartjsupp/suac069 |
Ejemplares similares
-
Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023) -
The many NOs to the use of Class IC antiarrhythmics: weren’t the guidelines too strict?
por: Turturiello, Dario, et al.
Publicado: (2022) -
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?
por: Cesaro, Arturo, et al.
Publicado: (2022) -
An aggressive solution for patients with heart failure and atrial fibrillation: nodal ablation and cardiac resynchronization therapy
por: Bianchi, Stefano, et al.
Publicado: (2022) -
Iron deficiency in heart failure: diagnosis and clinical implications
por: Del Pinto, Rita, et al.
Publicado: (2022)